[Form 4] Medtronic plc Insider Trading Activity

Rhea-AI Filing Summary

SVP & Chief Legal Officer Brett D. Pynnonen filed a Form 4 disclosing the sale of 1,200 Visteon (VC) common shares on 01-Aug-2025 at an average price of roughly $109.86 per share. Gross proceeds were about $0.13 million. After the transactions, Pynnonen’s direct ownership declined from 12,967 to 11,767 shares.

Positive

• Officer still holds 11,767 shares, preserving meaningful equity alignment.

Negative

• Insider sold 1,200 shares without a disclosed 10b5-1 plan, a mildly bearish governance signal.

Insights

Securities Analyst

TL;DR: Small insider sale; signal mildly negative but immaterial to fundamentals.

The divestiture represents ~9% of Pynnonen’s prior holdings and less than 0.04% of Visteon’s 28 m outstanding shares, so liquidity or valuation impact is negligible. No derivative activity or 10b5-1 plan was indicated, suggesting discretionary timing. Insider sales can hint at reduced confidence, yet executives routinely diversify portfolios. The officer retains ≈$1.3 m in stock, maintaining alignment with shareholders. Overall, the event is non-material to company outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martha Geoffrey

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MN 55432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/01/2025		M		57,724(1)	A	$0	283,700	D
Ordinary Shares	08/01/2025		F		26,323(2)	D	$89.34	257,377	D
Ordinary Shares	08/01/2025		F		13,054(3)	D	$89.34	244,323	D
Ordinary Shares	08/01/2025		M		40,600	A	$78	284,923	D
Ordinary Shares	08/01/2025		F		37,798	D	$89.34	247,125	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Units	(4)	08/01/2025		M			57,724	(5)	(5)	Performance Share Unit	57,724	$0	0	D
Stock Option (Right to Buy)	$78	08/01/2025		M			40,600	(6)	08/03/2025	Ordinary Shares	40,600	$0	0	D

Explanation of Responses:

1. Represents shares issued upon the settlement of performance-vesting restricted stock units granted on August 1, 2022 and earned dividend equivalents.

2. Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on August 1, 2025.

3. Represents shares withheld for taxes upon the vesting of restricted stock units previously reported on Table I.

4. Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

5. The performance share units vested on August 1, 2025.

6. These options became exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Visteon shares did Brett Pynnonen sell on 01-Aug-2025?

He sold 1,200 common shares in two transactions.

At what price were VC shares sold according to the Form 4?

The shares were sold at $109.85–$109.86 per share.

What is the executive’s remaining VC shareholding after the sale?

Pynnonen now directly owns 11,767 VC shares.

Does the filing reference a Rule 10b5-1 trading plan?

No box for 10b5-1 was checked; the sale appears discretionary.

Is this insider sale considered material to Visteon investors?

Given its small size versus total shares outstanding, it is not material.